68065-11-2

Basic information

• Product Name: 4-(3-BROMO-PROPOXY)-PHENOL
• Synonyms: 4-(3-BROMO-PROPOXY)-PHENOL;4-(3-broMopropoxy)-
• CAS NO: 68065-11-2
• Molecular Formula: C₉H₁₁BrO₂
• Molecular Weight: 231.09
• Product Categories: API intermediates
• Mol File: 68065-11-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 345.2°C at 760 mmHg
• Flash Point: 162.6°C
• Appearance: /
• Density: 1.462g/cm³
• Vapor Pressure: 3.14E-05mmHg at 25°C
• Refractive Index: 1.569
• PKA: 10.27±0.15(Predicted)
• CAS DataBase Reference: 4-(3-BROMO-PROPOXY)-PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMO-PROPOXY)-PHENOL(68065-11-2)
• EPA Substance Registry System: 4-(3-BROMO-PROPOXY)-PHENOL(68065-11-2)

Safety Data

• Hazardous Substances Data: 68065-11-2(Hazardous Substances Data)

Usage

Description

4-(3-Bromo-propoxy)-phenol is a chemical compound with the chemical formula C9H11BrO2. It is a derivative of phenol, featuring a bromine atom and a propoxy (CH3CH2CH2O) group attached to the phenol ring. 4-(3-BROMO-PROPOXY)-PHENOL is primarily used as an intermediate in the production of various chemical products.

Uses

Used in Pharmaceutical Industry:
4-(3-Bromo-propoxy)-phenol is used as an intermediate for the synthesis of pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(3-Bromo-propoxy)-phenol is used as an intermediate in the production of various agrochemicals. Its properties make it suitable for use in the development of pesticides and other agricultural chemicals.
Used in Dye Industry:
4-(3-Bromo-propoxy)-phenol is also used as an intermediate in the dye industry. Its chemical structure contributes to the creation of new dyes with specific color properties.
Used in Organic Synthesis:
4-(3-Bromo-propoxy)-phenol serves as a reagent in organic synthesis. Its bromine atom and propoxy group make it a versatile building block for the preparation of other organic compounds.
Used in Research and Development:
Although not widely studied for biological or toxicological effects, 4-(3-Bromo-propoxy)-phenol is used in research and development to explore its potential applications and properties. Proper handling and personal protective equipment are essential when working with this compound due to its potential hazards.

InChI:InChI=1/C9H11BrO2/c10-6-1-7-12-9-4-2-8(11)3-5-9/h2-5,11H,1,6-7H2

Upstream product

• 80199-92-4 1-benzyloxy-4-(3-bromopropoxy)benzene 
• 103-16-2 4-Benzyloxyphenol 
• 123-31-9 hydroquinone 
• 109-64-8 1,3-dibromo-propane 
• 108534-47-0 4-(tert-butyldimethylsilyloxy)phenol 

Downstream Products

• 910032-57-4 [4-(3-bromo-propoxy)-phenoxy]-acetic acid methyl ester 
• 841200-73-5 1-[3-(4-hydroxy-phenoxy)-propyl]-4-phenyl-piperidin-4-ol hydrogen bromide 
• 192872-86-9 2-Benzyl-1-(3-(4-hydroxyphenoxy)propyl)piperidine Hydrochloride 
• 1431659-37-8 4-(3-(ethyl(phenyl)amino)propoxy)phenol 

Relevant articles and documents

Ionic-liquid supported rapid synthesis of an: N -glycan core pentasaccharide on a 10 g scale

A new and efficient Ionic Liquid-Supported Oligosaccharide Synthesis (ILSOS) strategy for an N-linked core pentasaccharide on a 10 g scale is reported. This new ILSOS includes a new spacer for an IL support, a new tagging strategy, and fast, efficient and orthogonal removal of the ionic-liquid support, producing the N-linked core pentasaccharide with direct applicability potential in a short time, with high yield and on a large gram scale.

Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia

This study explores the possible use of reactive oxygen-activated DNA modifying agents against acute myeloid leukemia (AML). A key amine on the lead agent was investigated via cytotoxicity assays and was found necessary for potency. The two best compounds were screened via the NCI-60 cell panel. These two compounds had potency between 200 and 800 nM against many of the leukemia cancer cell types. Subsequent experiments explored activity against a transformed AML model that mimics the molecular signatures identified in primary AML patient samples. A lead compound had an IC50 of 760 nM against this AML cell line as well as a therapeutic index of 7.7 ± 3 between the transformed AML model cell line and non-cancerous human CD34+ blood stem/progenitor cells (UCB). The selectivity was much greater than the mainstays of AML treatment: doxorubicin and cytarabine. This manuscript demonstrates that this novel type of agent may be useful against AML.

LTA4H modulators and uses thereof

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.